Psilocybin and MDMA are gaining traction as breakthrough therapies for depression, with ongoing studies aiming for FDA approval. The future of psychedelic therapy lies in specialized clinics where trained therapists will guide patients through tailored experiences, potentially integrating various psychedelics based on individual needs. As the field evolves, cross-training in multiple substances will become essential for therapists, ensuring comprehensive care for patients and their families.
